← Leaderboards
Gennadiy Moiseyev
Columbia University Health Sciences
$2,581,356
Attributed
$5,506,967
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,506,967 · 5
By mechanism
R01$5,223,417 · 3
R43$283,550 · 2
Top collaborators
- Jian-Xing Ma11 shared
- Christopher L. Cioffi3 shared
- Konstantin Petrukhin3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- William S Blaner$18,785,143
- Robert F. Schwabe$23,538,022
- Christopher L. Cioffi$3,409,772
- Konstantin Petrukhin$4,542,112
- Filippo Mancia$14,879,578
Others in their field
Top investigators on “Retinoids”
- Krzysztof Palczewski · University Of California-Irvine$33,394,447
- John E Connett · University Of Minnesota Twin Cities$20,977,187
- Lorraine J Gudas · Sloan-Kettering Institute For Cancer Res$18,380,817
- Joseph L Napoli · University Of California Berkeley$14,913,548
- William S Blaner · Columbia University Health Sciences$13,070,813
- Garrett M Brodeur · Children'S Hospital Of Philadelphia$12,100,423
Research focus
RetinoidsRetinaVisionAbsorption11-Cis-RetinolEstersResponseRpe65 ProteinMutationVisual CyclePhotoreceptorsGenerationsGeneticOpsinGenesOptical Coherence TomographyProteinsOverexpressionEnzymesLecithin-Retinol AcyltransferasePathway InteractionsLight11 Cis RetinalKnock-Out
Grant awards (16)
Polypharmacological approach to treatment of Stargardt disease$619,139
R01 · FY2025 · EY
Studies of retinyl ester hydrolase in the visual cycle$387,501
R01 · FY2025 · EY
Polypharmacological approach to treatment of Stargardt disease$619,139
R01 · FY2024 · EY
Studies of retinyl ester hydrolase in the visual cycle$387,501
R01 · FY2024 · EY
Polypharmacological approach to treatment of Stargardt disease$645,138
R01 · FY2023 · EY
Studies of retinyl ester hydrolase in the visual cycle$387,501
R01 · FY2023 · EY
Studies of retinyl ester hydrolase in the visual cycle$375,876
R01 · FY2022 · EY
Studies of RPE65$334,857
R01 · FY2021 · EY
Studies of retinyl ester hydrolase in the visual cycle$316,619
R01 · FY2021 · EY
Studies of retinyl ester hydrolase in the visual cycle$45,879
R01 · FY2021 · EY
Studies of RPE65$16,767
R01 · FY2021 · EY
Studies of RPE65$362,500
R01 · FY2020 · EY
Studies of RPE65$362,500
R01 · FY2019 · EY
Studies of RPE65$362,500
R01 · FY2018 · EY
Cocktail of Angiogenic Inhibitors for the Treatment of Diabetic Macular Edema$133,750
R43 · FY2006 · EY · contact PI
Treatment of Retinal Vascular Leakage Using Angiostatin$149,800
R43 · FY2005 · EY